Hostname: page-component-7b9c58cd5d-bslzr Total loading time: 0.001 Render date: 2025-03-14T07:28:39.531Z Has data issue: false hasContentIssue false

Mechanisms of cisplatin ototoxicity: theoretical review

Published online by Cambridge University Press:  07 May 2013

M S Gonçalves*
Affiliation:
Department of Speech-Language Pathology and Audiology, Federal University of Santa Maria, Porto Alegre, Brazil
A F Silveira
Affiliation:
Department of Morphology/Health Sciences Center, Federal University of Santa Maria, Porto Alegre, Brazil
A R Teixeira
Affiliation:
Department of Developmental Psychology and Personality, Federal University of Rio Grande do Sul, Porto Alegre, Brazil
M A Hyppolito
Affiliation:
Department of Ophthalmology, Otorhinolaryngology and Head and Neck Surgery, Ribeirão Preto Medical School, University of São Paulo, Brazil
*
Address for correspondence: Dr Maiara S Gonçalves, Avenida Evaldo Behr, 02 Parque Residencial Novo Horizonte, Bairro Camobi, Santa Maria, RS 97110-801, Brazil Fax: +55 55 3301 1166 E-mail: maiarasg@yahoo.com.br
Rights & Permissions [Opens in a new window]

Abstract

Introduction:

Cisplatin is an effective chemotherapeutic agent commonly used in the treatment of malignant tumours, but ototoxicity is a significant side effect.

Objectives:

To discuss the mechanisms of cisplatin ototoxicity and subsequent cell death, and to present the results of experimental studies.

Material and methods:

We conducted a systematic search for data published in national and international journals and books, using the Medline, SciELO, Bireme, LILACS and PubMed databases.

Results:

The nicotinamide adenine dinucleotide phosphate oxidase 3 isoform (also termed NOX3) seems to be the main source of reactive oxygen species in the cochlea. These reactive oxygen species react with other molecules and trigger processes such as lipid peroxidation of the plasma membrane and increases in expression of the transient vanilloid receptor potential 1 ion channel.

Conclusion:

Cisplatin ototoxicity proceeds via the formation of reactive oxygen species in cochlear tissue, with apoptotic cell death as a consequence.

Type
Review Articles
Copyright
Copyright © JLO (1984) Limited 2013 

Introduction

Cisplatin (cis-diamminedichloroplatinum II) is a highly effective chemotherapeutic agent commonly used in the treatment of several malignant tumours,Reference Wang and Lippard1 especially those of the head and neck,Reference Jordan, Schwade and Truelson2 in adults and children.Reference Hyppolito and Oliveira3 Cisplatin acts in the tumour cell through mechanisms such as DNA damage and production of reactive oxygen species, which lead to cell death by apoptosis. Cell death can also occur via necrosis when the cell is exposed to high concentrations of cisplatin.Reference Wang and Lippard1

The clinical administration of cisplatin is limited by its side effects, which include nephrotoxicity, ototoxicity, neurotoxicity, gastrointestinal tract toxicity and bone marrow toxicity (i.e. myelosuppression).Reference Saleh and El-Demerdash4 Nephrotoxicity can be managed with hydration and administration of mannitol, diuretics or acetozolamide, and thiol compounds.Reference Bates, Beaumont and Baylis5 Some other side effects can be mitigated with fractionated doses of medication.Reference Ilha, Kasse, Mesquita Neto, Almeida and Cruz6 However, there appears to be no effective medical treatment for the prevention or control of ototoxicity,Reference Rybak, Mukherjea, Jajoo and Ramkumar7 although the use of antioxidant therapy has been shown to be beneficial in animal models.Reference Rybak and Kelly8

Histopathological studies of cisplatin ototoxicity indicate that damage to the outer hair cells progresses from the base to the apex of the cochlea and from the third to the first row of these cells, after which damage progresses to the inner hair cells.Reference Schweitzer9, Reference Hinojosa, Riggs, Strauss and Matz10 Damage is not limited to the hair cells – the supporting cells, stria vascularis and spiral ganglion are also affected.Reference Hyppolito and Oliveira3 However, Lee et al. Reference Lee, Nakagawa, Kita, Kim, Iguchi and Endo11 have suggested that the stria vascularis of the cochlea is the region initially affected, leading to impaired uptake and secretion of potassium into the endolymph as well as impairment of the metabolic homeostasis of inner and outer hair cells, with resultant structural and functional damage.

The dose of cisplatin is an important determinant of the extent of ototoxic damage, a relationship first described in the 1980s and 1990s. When low doses were used, the stereocilia tip-link connections were damaged first, followed by disorganisation and fusion of stereocilia.Reference Comis, Rhys-Evans, Osborne, Pickles, Jeffries and Pearse12 High doses result in mitochondrial and endoplasmic reticulum damage, loss of stereocilia and of the hair cell itself, atrophy of the stria vascularis, collapse of Reissner's membrane, and damage to supporting cells.Reference Estrem, Babin, Ryu and Moore13 Neurotoxicity occurs via a direct action on neurons, or via a secondary mechanism whereby hair cell toxicity results in the loss of trophic factors produced by healthy cells and supplied to the neurons that innervate them.Reference Feghali, Lefebvre, Staecker, Kopke, Frenz and Malgrange14

Besides the dose, other factors may affect the variability and severity of cisplatin ototoxicity, including patient age, renal function, interaction with other substances (e.g. antibiotics and diuretics), aminoglycosides, pre-existing hearing loss, and duration and form of cisplatin infusion.Reference Simon, Hero, Dupuis, Selle and Berthold15

Clinically, cisplatin causes irreversible, bilateral, sensorineural hearing loss associated with tinnitus, which affects primarily the high frequencies and subsequently the low ones.Reference Casares, Ramírez-Camacho, Trinidad, Roldán, Jorge and García-Berrocal16 High frequency hearing loss has been reported to affect between 50 per centReference Stavroulaki, Apostolopoulos, Segas, Tsakanikos and Adamopoulos17 and 100 per centReference Garcia, Iório and Petrilli18 of patients. Children are more susceptible than adults.Reference Li, Womer and Silber19

Given this framework, the current study aimed to discuss the mechanisms of cisplatin ototoxicity and consequent cell death, as well as to present the results of experimental research.

Method

Systematic collection of data from national (i.e. Brazilian) and international journals was undertaken, using the Medline, SciELO, Bireme, LILACS and PubMed databases. Sixty-six relevant papers were selected, published from the 1980s to the present day, comprising 54 international and 12 national papers. We also obtained information from one internationally published and two Brazilian books.

Literature review

Free radicals due to cisplatin in the cochlea

There are several different mechanisms by which cisplatin damages the auditory system and triggers the apoptotic cell death pathway. One of these relates to the following sequence: covalent binding of cisplatin to guanine bases in DNA; formation of inter- and intra-strand chain crosslinking; induced p53; cell cycle arrest; and apoptosis. A second mechanism, currently widely discussed, refers to the generation of free radicals, specifically reactive oxygen species, which can increase lipid peroxidation, alter enzyme and structural proteins, and cause apoptotic cell death.Reference Casares, Ramírez-Camacho, Trinidad, Roldán, Jorge and García-Berrocal16

Free radicals are atoms or molecules that contain an unusual number of electrons in their outer electron layer because they have undergone the process of oxidation (i.e. electron loss); thus, free radicals are products of oxidation.Reference Schneider and Oliveira20 The non-pairing of the electrons of the outer layer confers high reactivity to these atoms or molecules.Reference Ferreira and Matsubara21

Oxidation is a fundamental part of human metabolism.Reference Barreiros, David and David22 Reactive oxygen species are formed by normal cellular metabolism (e.g. mitochondrial respiration), inflammatory processes, and in response to irradiation, chemotherapeutic agents and some antibiotics.Reference Freeman and Crapo23 Although oxygen radicals play an essential biological role, they are also potent oxidants, subtracting electrons from other molecules that interact with them and thereby converting those molecules into free radicals themselves, thus creating a cascade of damage which has been termed ‘oxidative stress’.Reference Kumar, Abbas and Fausto24

In order to combat the reactive oxygen species formed by cellular respiration or in response to xenobiotics, as well as to keep the oxidative system balanced, cells use an endogenous antioxidant system. This system consists of enzymes, such as reduced glutathione, superoxide dismutase, catalase and glutathione peroxidase, which act before cell damage occurs and play a detoxification role. Ross and Moldeus have described a defence system which includes ascorbic acid, glutathione reductase and glutathione peroxidase, among others, and which acts to repair the damage caused by reactive oxygen species.Reference Ross, Moldeus and Vigo-Pelfrey25

Cochlear antioxidant systems include glutathione, glutathione peroxidase, glutathione reductase, superoxide dismutase and catalase.Reference Rybak, Mukherjea, Jajoo and Ramkumar7

Once generated, and if not controlled by antioxidant systems, reactive oxygen species can react with a variety of cellular components and cause damaging alterations, such as aldehydic lipid peroxidation of membranes, oxidative modifications of proteins, and DNA lesions.Reference Gutteridge and Halliwell26

In the cochlea, cisplatin accumulates in the tissue, integrates with cellular DNA and causes dysfunction in protein synthesis, including antioxidant enzymes. Since the cochlea is in an isolated anatomical position, and effectively functions almost as a closed system, it is unable to expel the toxin at the same rate at which it is accumulated. Thus, an overload of reactive oxygen species develops, associated with an impaired antioxidant system.Reference Rybak, Husain, Morris, Whitworth and Somani27 This state results in increased lipid peroxidation, triggering events that initiate the apoptosis of hair cells, supporting cells, stria vascularis and the auditory nerve.Reference Campbell, Kalkanis and Glatz28

Degeneration of the stria vascularis is one of the first events in the development of cisplatin-induced hearing loss. Reactive oxygen species in the stria vascularis cause mitochondrial membrane permeabilisation and apoptosis of marginal cells.Reference Lee, Nakagawa, Kita, Kim, Iguchi and Endo11

Apoptotic cell death (which is beneficial in cancer cells) is the basis for understanding cisplatin toxicity in healthy tissues such as the cochlea.Reference Van Rujven, De Groot, Hendriksen and Smoorenburg29

The nicotinamide adenine dinucleotide phosphate oxidase 3 isoform (also termed NOX3) is now thought to play a central role in oxidation within the cochlea. This isoform is exclusively found in the inner ear and appears to contribute significantly to the generation of reactive oxygen species within the cochlea.Reference Mukherjea, Jajoo, Whitworth, Bunch, Turner and Rybak30, Reference Bánfi, Malgrange, Knisz, Steger, Dubois-Dauphin and Krause31

In organotypic cultures, when activated by cisplatin, the nicotinamide adenine dinucleotide phosphate oxidase 3 isoform produces superoxide radical (O2·).Reference Bánfi, Malgrange, Knisz, Steger, Dubois-Dauphin and Krause31, Reference Rybak32 The excess of reactive oxygen species in the cochlear tissue can react with nitric oxide to generate peroxynitrite, which can inactivate proteins.Reference Lee, Nakagawa, Kita, Kim, Iguchi and Endo11 Furthermore, superoxide radical may form hydroxyl radical (OH) in its free form, and this ion may react with unsaturated fatty acids in the lipid bilayer of the cell membrane to generate aldehyde 4-hydroxynonenal, which is highly toxic and may lead to cell death. The increase in aldehyde 4-hydroxynonenal concentration is associated with an increased calcium influx to the outer hair cells, leading to apoptosis.Reference Ikeda, Sunose and Takasaka33 The superoxide anion may also inactivate antioxidant enzymesReference Pigeolet, Corbisier, Houbion, Lambert, Michiels and Raes34 and cause migration of the pro-apoptotic Bax protein to the cytosol, resulting in the release of cytochrome c from the damaged mitochondria and the consequent activation of caspases 9 and 3.Reference Rybak, Mukherjea, Jajoo and Ramkumar7

In addition to the above-mentioned plasma membrane lipid peroxidation and effects on cochlear tissue, reactive oxygen species may also activate and increase the expression of the transient vanilloid receptor potential 1 ion channel (also termed receptor transient potential V1).Reference Mukherjea, Jajoo, Whitworth, Bunch, Turner and Rybak30 This is a member of the transient receptor potential family of ion channel proteins, and is expressed primarily in small diameter neuronsReference Caterina, Schumacher, Tominaga, Rosen, Levine and Julius35 and non-neuronal tissues (e.g. the organ of Corti).Reference Southall, Li, Gharibova, Pei, Nicol and Travers36, Reference Zheng, Dai, Steyger, Kim, Vass and Ren37 Increased expression of transient vanilloid receptor potential 1 contributes to cell death by increasing the influx of calcium into the cell, with consequent calcium overload, and by activation of caspases.Reference Casares, Ramírez-Camacho, Trinidad, Roldán, Jorge and García-Berrocal16, Reference Mukherjea, Jajoo, Whitworth, Bunch, Turner and Rybak30

Apoptotic cell death due to reactive oxygen species in the cochlea

Apoptosis of cochlear cells may be precipitated by the complex interaction between cisplatin and the DNA of the damaged cell, preventing normal cell cycle progression.Reference Devarajan, Savoca, Castaneda, Park, Esteban-Cruciani and Kalinec38 In addition, drug-induced oxidative stress triggers a cascade of intracellular reactions that culminates in apoptosis.Reference Ravi, Somani and Rybak39

Apoptosis is a cell death pathway induced by a highly regulated cellular programmeReference Kumar, Abbas and Fausto24 involving programmed cell death and ‘suicide’ cells.Reference Strayer, Rubin, Rubin, Gorstein, Rubin, Schwarting and Strayer40 It can be triggered by several physiological situations, such as the destruction of cells during embryogenesis,Reference Kumar, Abbas and Fausto24 or due to factors such as chemotherapeutic agents, ionising radiation, DNA damage, heat shock, growth factor deprivation, nutrient deficiency, binding of molecules to membrane receptors, and increased levels of reactive oxygen species.Reference Hengartner41

The morphological and biochemical characteristics of apoptosis involve nuclear fragmentation, chromatin condensation, cell shrinkage, ‘bubbling’ of the cellular surface with maintenance of membrane integrity, apoptotic body formation and proteolysis (i.e. protein degradation by enzymes). Cell debris are phagocytosed by neighbouring cells or macrophages.Reference Huang, Cheng, Stupak, Liu, Kim and Staecker42

For some years, the specific intracellular proteases of the caspase family have been investigated as crucial effectors of apoptosis.Reference Adams and Cory43

The caspases (which derive their name from cysteine aspartic acid proteases) are based on cysteine proteases able to cleave other proteins after an aspartic acid residue,Reference Strasser, O'Connor and Dixit44 and are synthesised as inactive precursors known as zymogens (pro-caspase).Reference Hengartner41 The caspase family can be divided functionally into initiator caspases and effector caspases, depending on the order in which they are activated during apoptosis. The initiator caspases include types 8 and 9, while the effector caspases include types 3, 6 and 7, among others.Reference Kumar, Abbas and Fausto24

The pro-caspases are activated by proteolytic cleavage of caspases when the cell receives a signal for cell death.Reference Boatright and Salvesen45 Once activated, they operate in a cascade fashion, that is, the initiator caspases activate the effector caspases which in turn effect the fragmentation of cellular DNA.Reference Sharifia, Eslami, Larijani and Davoodi46

The apoptotic process can be triggered by two pathways, one extrinsic (cytoplasmic) and the other intrinsic (mitochondrial), both of which converge to activate effector caspases.Reference Grivicich, Regner and Rocha47 Furthermore, these routes can be classified according to the type of pro-caspase that is activated. In the extrinsic pathway, activation of pro-caspase 8 (an initiator caspase) results from signalling of a cell surface death receptor, such as Fas or tumour necrosis factor receptor 1. In the intrinsic pathway, the activation of pro-caspase 9 (an initiator caspase) is mainly dependent on the mitochondrial signalling pathway regulated by members of the Bcl-2 (B-cell lymphoma 2) family.Reference Harris and Thompson48 The Bcl-2 family is composed of 25 anti- and pro-apoptotic members.Reference Borner49 The activation of the pro-apoptotic members of the Bcl-2 family, such as Bax protein, may trigger a sequence of events that lead to changes in mitochondrial permeability and the release of cytochrome c (a caspase activator protein) into the cytoplasm, which binds to another protein (protease activating factor in apoptosis 1, also termed ‘Apaf-1’) to form a protein complex (apoptosome) that activates pro-caspase 9.Reference Golstein, Waterhouse, Juin, Evan and Green50 Once activated, caspases 8 and 9 both participate in a cascade of events leading to the activation of caspase 3, which cleaves various substrates and results in DNA fragmentation and the morphological characteristics of cell apoptosis.Reference Thornberry and Lazebnik51 In contrast, the Bcl-2 protein, a member of the anti-apoptotic Bcl-2 family, promotes cell survival by preventing the escape of cytochrome c into the cytoplasm, possibly by forming heterodimers with pro-apoptotic molecules such as Bax protein.Reference Amarante-Mendes and Green52

Decreased transcription of the anti-apoptotic protein Bcl-2 and increased transcription of the pro-apoptotic Bax protein are mediated by the p53 gene. This is a tumour suppressor gene that accumulates in the cell when DNA is damaged, causing suspension of the cell cycle at the G1 phase and facilitating DNA repair. However, if the repair fails, p53 triggers apoptosis by stimulating the transcription of pro-apoptotic proteins and decreasing the transcription of anti-apoptotic proteins.Reference Kumar, Abbas and Fausto24

The mitochondrial dysfunction that triggers the intrinsic apoptosis pathway can be caused by intracellular stress signals resulting from DNA damage, toxins or oxidative stress, among others.Reference Paronlin and Reason53

Devarajan et al. Reference Devarajan, Savoca, Castaneda, Park, Esteban-Cruciani and Kalinec38 have confirmed the involvement of both extrinsic pathway (death receptor) and intrinsic pathway (mitochondrial) apoptosis induced by cisplatin in an in vitro model of auditory cells.

Results of experimental research

Several studies on the auditory effects of cisplatin have been conducted. Important findings are summarised below, to provide an overview and to help guide subsequent studies.

In 1995, Ravi, Somani and RybakReference Ravi, Somani and Rybak39 induced ototoxicity in rats by administering different doses of cisplatin. These authors found that the cisplatin ototoxicity was associated with decreased activity of glutathione peroxidase and glutathione reductase, compared with controls. They also found increased activity of superoxide dismutase and catalase three days after cisplatin administration, suggesting an increased concentration of reactive oxygen species within the cochlea and an impaired cochlear antioxidant system. There was also an accumulation of malondialdehyde, an indicator of lipid peroxidation.

Alam et al. Reference Alam, Ikeda, Oshima, Suzuki, Kawase and Kikuchi54 administered cisplatin (4 mg/kg/day) for 5 consecutive days and subsequently identified apoptotic cells in all cochlear structures, including the inner and outer hair cells, supporting cells, spiral ganglion, stria vascularis, and spiral ligament. An increase in the expression of Bax protein and a decrease in Bcl-2 suggested the importance of the Bcl-2 protein family in the control of cisplatin-related apoptosis. In addition, Liu et al. Reference Liu, Staecker, Stupak, Malgrange, Lefebvre and Van De Water55 and Cheng et al. Reference Cheng, Liu, Hsu and Lin-Shiau56 studied organ of Corti cell cultures from 3-day-old rats and demonstrated the role of apoptosis as a mechanism of cisplatin-induced cell damage.

The extent and degree of histological and functional auditory system damage appear to be related to the cisplatin dose administered. Different methodologies have been studied, in guinea pig models, in order to investigate this relationship. Applying a dosage of 1 mg/kg/day for 4, 8, 12 and 16 days, SchweitzerReference Schweitzer9 suggested that a cumulative dose of 16 mg/kg was required to cause maximal cell loss (78 per cent in this study). Cardinaal et al. Reference Cardinaal, de Groot, Huizing, Veldman and Smoorenburg57 reported maximal (i.e. 65 per cent) loss of the outer hair cells of the basal turn of the cochlea following a dosage of 2 mg/kg/day for eight days (also representing a cumulative dose of 16 mg/kg).

In order to establish the optimal cisplatin dose, and dose administration, required to achieve significant cell damage, Ilha et al. Reference Ilha, Kasse, Mesquita Neto, Almeida and Cruz6 studied 48 female albino guinea pigs divided into four groups (each containing nine animals in the final analysis) receiving four different intraperitoneal cisplatin regimes: (1) a single dose of 7.5 mg/kg/day; (2) two doses of 7.5 mg/kg/day for the first and fifth day; (3) three doses of 7.5 mg/kg/day for the first, fifth and sixth day; or (4) doses of 2.5 mg/kg/day for the first, second, third, fourth, fifth and sixth day. Animals underwent distortion product otoacoustic emission (DPOAE) testing during cisplatin treatment. Following sacrifice, the animals' cochleae were analysed by scanning electron microscopy. The authors found lesions in 70 per cent of the outer hair cells in the first and second turns in animals receiving 7.5 mg/kg/day cisplatin on the first, fifth and sixth days. These findings were confirmed by DPOAE results. Despite these substantially auditory effects, other clinical effects were such that animals were still able to be kept for periods of up to 21 days. This dosing regimen was used in further studies, together with otoprotectors.Reference Kasse, Hyppolito, Cruz and Oliveira58

Rybak et al. Reference Rybak, Whitworth and Somani59 studied rats treated with a single dose of 16 mg/kg cisplatin, and found significant changes in brainstem evoked auditory potential threshold and decreased intracellular glutathione levels (to 53 per cent in a control group). Decreased levels of antioxidant enzymes were also found, i.e. superoxide dismutase (to 52 per cent of the control level), glutathione reductase (to 50 per cent of the control level), catalase (to 70 per cent of the control level) and glutathione peroxidase (to 50 per cent of the control level). Membrane lipid peroxidation was also observed, as indicated by a malondialdehyde level increase to 165 per cent compared with the control group level.

Freitas et al. Reference Freitas, Figueiredo, Brito, Leitão, Carvalho and Gomes60 investigated the role of apoptosis in cisplatin-induced cochlear injury using a male Wistar rat model. The animals were divided into eight groups distinguished by differing cisplatin dose, administration mode, and assessment type and timing (DPOAE and brainstem evoked auditory potentials were used). The most relevant of these test results showed that, in mice receiving 8 mg/kg/day of cisplatin for 3 consecutive days (a cumulative dose of 24 mg/kg), there was a significant decrease in DPOAE amplitudes on the third day, but that animals receiving a single, 16 mg/kg dose showed no such result. A significant increase in electrophysiological thresholds was observed on the third and fourth day after receipt of either a single cisplatin dose of 16 mg/kg or a cumulative dose of 24 mg/kg. This study also performed immunohistochemical analysis of tissue using the membranous labyrinth terminal deoxyribonucleotidyl transferase mediated deoxyuridine triphosphate digoxigenin nick end labelling assay (also termed TUNEL assay), which showed significantly greater staining intensity in the cochleae of animals treated with a single cisplatin dose of 16 mg/kg. Apoptosis immunostaining was seen in the inner and outer hair cells, supporting cells, stria vascularis, spiral ligament, spiral limbus, and spiral ganglion.

Cisplatin-induced cochlear cell damage shows two peculiarities: firstly, the outer hair cells of the cochlear base are inherently more susceptible to free radical damage than the outer hair cells of the cochlear apex; and secondly, supporting cells have considerably greater survival capacity than sensory cells. Sha et al. Reference Sha, Taylor, Forge and Schacht61 reported that glutathione levels were higher in the apical outer hair cells compared with the basal cells, which suggests a differential susceptibility to damage via varying sensitivity to the action of reactive oxygen species. However, Usami et al. Reference Usami, Hjelle and Ottersen62 reported that the protective mechanisms provided by endogenous cellular antioxidants such as glutathione and enzymes such as superoxide dismutase and glutathione peroxidase provide a primary defence against free radicals. This protective mechanism may be distributed differently within various cells of the cochlea.

Given the irreversible nature of cisplatin-induced hearing loss, other studies have investigated the action of potentially otoprotective substances coadministered with cisplatin, with some promising positive results. Such potentially otoprotective substances include fosfomycin,Reference Jordan, Schwade and Truelson2 sodium thiosulfate,Reference Muldoon, Pagel, Kroll, Brummett, Doolittle and Zuhowski63 amifostine,Reference Hyppolito, Oliveira, Lessa and Rossato64Ginkgo biloba extract,Reference Hyppolito, Oliveira, Rossato and Holanda65 vitamin EReference Kalkanis, Whitworth and Rybak66 and N-acetylcysteine,Reference Feghali, Liu and Van De Water67Reference Riga, Chelis, Kakolyris, Papadopoulos, Stathakidou and Chamalidou69 among others.

Conclusion

The presence of cisplatin triggers a series of events in the cochlea which are harmful to cell survival. There is evidence that this process begins with activation of the nicotinamide adenine dinucleotide phosphate oxidase 3 isoform, which is considered the main source of reactive oxygen species within the cochlea, with consequent impaired synthesis of the antioxidant enzymes which normally play a fundamental role in cellular oxidative balance. Thus, cochlear tissue is placed under oxidative stress, with the production of reactive oxygen species working in opposition to the antioxidant system.

Reactive oxygen species cause damage via plasma membrane lipid peroxidation and alteration of proteins and DNA. When these lesions are not repaired by the cellular defence system, the cell crosses the threshold of reversible injury and recognises that repair has failed; thereafter, activation of the apoptosis pathway programmes the cell to die.

The biochemical process of apoptosis proceeds via two main pathways: extrinsic (also termed cytoplasmic) and intrinsic (also termed mitochondrial). Both pathways converge to produce caspase 3 activation, DNA fragmentation and formation of apoptotic bodies which are then phagocytosed.

This paper aims to discuss some of the important aspects of the cisplatin ototoxicity mechanism. However, there is still much to be clarified, and the continuation of experimental research is essential for this purpose.

References

1Wang, D, Lippard, SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 2005;4:307–20CrossRefGoogle ScholarPubMed
2Jordan, JA, Schwade, ND, Truelson, JM. Fosfomycin does not inhibit the tumoricidal efficacy of cisplatinum. Laryngoscope 1999;109:1259–62CrossRefGoogle Scholar
3Hyppolito, MA, Oliveira, JA. Ototoxicity, otoprotection and self defense of the cochlear outer hair cells [in Brazilian Portuguese]. Medicina (Ribeirão Preto) 2005;38:279–89CrossRefGoogle Scholar
4Saleh, S, El-Demerdash, E. Protective effects of L-arginine against cisplatin-induced renal oxidative stress and toxicity: role of nitric oxide. Basic Clin Pharmacol Toxicol 2005;97:91–7CrossRefGoogle ScholarPubMed
5Bates, DE, Beaumont, SJ, Baylis, BW. Ototoxicity induced by gentamicin and furosemide. Ann Pharmacother 2002;36:446–51CrossRefGoogle ScholarPubMed
6Ilha, L, Kasse, C, Mesquita Neto, O, Almeida, CR, Cruz, OLM. Cisplatin-induced ototoxicity in guinea pigs: dose-related effects – a functional evaluation [in Brazilian Portuguese]. ACTA ORL/Técnicas em Otorrinolaringologia 2007;25:112–18Google Scholar
7Rybak, LP, Mukherjea, D, Jajoo, S, Ramkumar, V. Cisplatin ototoxicity and protection: clinical and experimental studies. Tohoku J Exp Med 2009;219:177–86CrossRefGoogle ScholarPubMed
8Rybak, LP, Kelly, T. Ototoxicity: bioprotective mechanisms. Curr Opin Otolaryngol Head Neck Surg 2003;11:328–33CrossRefGoogle ScholarPubMed
9Schweitzer, VG. Cisplatin-induced ototoxicity: the effect of pigmentation and inhibitory agents. Laryngoscope 1993;103:152Google ScholarPubMed
10Hinojosa, R, Riggs, LC, Strauss, M, Matz, GJ. Temporal bone histopathology of cisplatin ototoxicity. Am J Otol 1995;16:731–41Google ScholarPubMed
11Lee, JE, Nakagawa, T, Kita, T, Kim, TS, Iguchi, F, Endo, T et al. Mechanisms of apoptosis induced by cisplatin in marginal cells in mouse stria vascularis. ORL J Otorhinolaryngol Relat Spec 2004;66:111–18CrossRefGoogle ScholarPubMed
12Comis, SD, Rhys-Evans, PH, Osborne, MP, Pickles, JO, Jeffries, DJR, Pearse, HAC. Early morphological and chemical changes induced by cisplatin in the guinea pig organ of Corti. J Laryngol Otol 1986;100:1375–83CrossRefGoogle ScholarPubMed
13Estrem, SA, Babin, RW, Ryu, JH, Moore, KC. Cis-Diamminedichloroplatinum (II) ototoxicity in the guinea pig. Otolaryngol Head Neck Surg 1981;89:638–45CrossRefGoogle ScholarPubMed
14Feghali, JG, Lefebvre, PP, Staecker, H, Kopke, R, Frenz, DA, Malgrange, B et al. Mammalian auditory hair cell regeneration/repair and protection: a review and future directions. Ear Nose Throat J 1998;77:276–85CrossRefGoogle ScholarPubMed
15Simon, T, Hero, B, Dupuis, W, Selle, B, Berthold, F. The incidence of hearing impairment after successful treatment of neuroblastoma. Klin Pediatr 2002;214:149–52CrossRefGoogle ScholarPubMed
16Casares, C, Ramírez-Camacho, R, Trinidad, A, Roldán, A, Jorge, E, García-Berrocal, JR. Reactive oxygen species in apoptosis induced by cisplatin: review of physiopathological mechanisms in animal models. Eur Arch Otorhinolaryngol 2012;269:2455–9CrossRefGoogle ScholarPubMed
17Stavroulaki, P, Apostolopoulos, N, Segas, J, Tsakanikos, M, Adamopoulos, G. Evoked otoacoustic emissions – an approach for monitoring cisplatin induced ototoxicity in children. Int J Pediatr Otorhinolaryngol 2001;59:4757CrossRefGoogle ScholarPubMed
18Garcia, AP, Iório, MCM, Petrilli, AS. Audiological monitoring of cisplatin exposed patients [in Brazilian Portuguese]. Rev Bras Otorrinolaringol 2003;69:215–21CrossRefGoogle Scholar
19Li, Y, Womer, RB, Silber, JH. Predicting cisplatin ototoxicity in children: influence of age and the cumulative dose. Eur J Cancer 2004;40:2445–51CrossRefGoogle ScholarPubMed
20Schneider, CD, Oliveira, AR. Oxygen free radicals and exercise: mechanisms of synthesis and adaptation to physical training [in Brazilian Portuguese]. Rev Bras Med Esporte 2004;10:308–13CrossRefGoogle Scholar
21Ferreira, ALA, Matsubara, LS. Free radicals: concepts, diseases, defense system and oxidative stress [in Brazilian Portuguese]. Rev Assoc Med Bras 1997;43:61–8Google ScholarPubMed
22Barreiros, ALBS, David, JM, David, JP. Oxidative stress: relations between the formation of reactive species and the organism's defense [in Brazilian Portuguese]. Quim Nova 2006;29:113–23CrossRefGoogle Scholar
23Freeman, BA, Crapo, JD. Biology of disease: free radical and tissue injury. Lab Invest 1982;47:412–26Google ScholarPubMed
24Kumar, V, Abbas, AK, Fausto, N. Cellular injury, cell adaptation and cell death. In: Robbins and Cotran: Pathologic Basis of Disease, 7th edn.Philadelphia: Elsevier, 2005;1148Google Scholar
25Ross, D, Moldeus, P. Antioxidant defense systems and oxidative stress. In: Vigo-Pelfrey, C. Membrane Lipid Oxidation. Boca Raton: CRC Press, 1991;151–70Google Scholar
26Gutteridge, JMC, Halliwell, B. Antioxidants: molecules, medicines and myths. Biochem Biophys Res Commun 2010;393:561–4CrossRefGoogle ScholarPubMed
27Rybak, LP, Husain, K, Morris, C, Whitworth, C, Somani, S. Effect of protective agents against cisplatin ototoxicity. Am J Otol 2000;21:513–20Google ScholarPubMed
28Campbell, KCM, Kalkanis, J, Glatz, FR. Ototoxicity: mechanisms, protective agents and monitoring. Curr Opin Otol Head Neck Sur 2000;8:436–40CrossRefGoogle Scholar
29Van Rujven, MWM, De Groot, JCMJ, Hendriksen, F, Smoorenburg, GF. Immunohistochemical detection of platinated DNA in the cochlea of cisplatin-treated guinea pigs. Hear Res 2005;203:112–21CrossRefGoogle Scholar
30Mukherjea, D, Jajoo, S, Whitworth, CA, Bunch, JR, Turner, JG, Rybak, LP et al. Short interfering RNA against transient receptor potential vanilloid-1 attenuates cisplatin-induced hearing loss in the rat. J Neurosci 2008;28:13056–65CrossRefGoogle ScholarPubMed
31Bánfi, B, Malgrange, B, Knisz, J, Steger, K, Dubois-Dauphin, M, Krause, K-H. NOX3, a superoxide-generating NADPH oxidase of the inner ear. J Biol Chem 2004;279:46065–72CrossRefGoogle ScholarPubMed
32Rybak, LP. Mechanisms of cisplatin ototoxicity and progress in otoprotection. Curr Opin Otolaryngol Head Neck Surg 2007;15:364–9CrossRefGoogle ScholarPubMed
33Ikeda, K, Sunose, H, Takasaka, T. Effects of free radicals on the intracellular calcium concentration in the isolated hair cell of the guinea pig cochlea. Acta Otolaryngol 1993;113:137–41CrossRefGoogle ScholarPubMed
34Pigeolet, E, Corbisier, P, Houbion, A, Lambert, D, Michiels, C, Raes, M et al. Glutathione peroxidase, superoxide dismutase and catalase inactivation by peroxides and oxygen derived free radicals. Mech Ageing Dev 1990;50:283–97CrossRefGoogle Scholar
35Caterina, MJ, Schumacher, MA, Tominaga, M, Rosen, TA, Levine, JD, Julius, D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 1997;389:816–24CrossRefGoogle ScholarPubMed
36Southall, MD, Li, T, Gharibova, LS, Pei, Y, Nicol, GD, Travers, JB. Activation of epidermal vanilloid receptor-1 induces release of proinflammatory mediators in human keratinocytes. J Pharmacol Exp Ther 2003;304:217–22CrossRefGoogle ScholarPubMed
37Zheng, J, Dai, C, Steyger, PS, Kim, Y, Vass, Z, Ren, T et al. Vanilloid receptors in hearing: altered cochlear sensitivity by vanilloids and expression of TRPV1 in the organ of corti. J Neurophysiol 2003;90:444–55CrossRefGoogle ScholarPubMed
38Devarajan, P, Savoca, M, Castaneda, MP, Park, MS, Esteban-Cruciani, N, Kalinec, G et al. Cisplatin-induced apoptosis in auditory cells: role of death receptor and mitochondrial pathways. Hear Res 2002;174:4554CrossRefGoogle ScholarPubMed
39Ravi, R, Somani, SM, Rybak, LP. Mechanism of cisplatin ototoxicity: antioxidant system. Pharmacol Toxicol 1995;76:386–94CrossRefGoogle ScholarPubMed
40Strayer, DS, Rubin, E. Cell injury. In: Rubin, E, Gorstein, F, Rubin, R, Schwarting, R, Strayer, D. Rubin's Pathology: Clinicopathologic Foundations of Medicine, 4th edn [in Brazilian Portuguese]. São Paulo: Guanabara-Koogan, 2006;239Google Scholar
41Hengartner, MO. The biochemistry of apoptosis. Nature 2000;407:770–6CrossRefGoogle ScholarPubMed
42Huang, T, Cheng, AG, Stupak, H, Liu, W, Kim, A, Staecker, H et al. Oxidative stress-induced apoptosis of cochlear sensory cells: otoprotective strategies. Int J Dev Neurosci 2000;18:259–70CrossRefGoogle ScholarPubMed
43Adams, JM, Cory, S. The Bcl-2 protein family: arbiters of cell death. Science 1998;281:1322–6CrossRefGoogle Scholar
44Strasser, A, O'Connor, L, Dixit, VM. Apoptosis signaling. Annu Rev Biochem 2000;69:217–45CrossRefGoogle ScholarPubMed
45Boatright, KM, Salvesen, GS. Mechanisms of caspase activation. Curr Opin Cell Biol 2003;15:725–31CrossRefGoogle ScholarPubMed
46Sharifia, AM, Eslami, H, Larijani, B, Davoodi, J. Involvement of caspase-8, 9, and 3 in high glucose-induced apoptosis in PC12 cells. Neurosci Lett 2009;459:4751CrossRefGoogle Scholar
47Grivicich, I, Regner, A, Rocha, AB. Apoptosis: programmed cell death [in Brazilian Portuguese]. Rev Bras Cancerol 2007;53:335–43CrossRefGoogle Scholar
48Harris, MH, Thompson, CB. The role of the Bcl-2 family in the regulation of outer mitochondrial membrane permeability. Cell Death Differ 2000;7:1182–91CrossRefGoogle ScholarPubMed
49Borner, C. The Bcl-2 protein family: sensors and checkpoints for life-or-death decisions. Mol Immunol 2003;39:615–47CrossRefGoogle ScholarPubMed
50Golstein, JC, Waterhouse, NJ, Juin, P, Evan, GI, Green, DR. The coordinate release of cytochrome c during apoptosis is rapid, complete and kinetically invariant. Nature Cell Biol 2000;2:156–62CrossRefGoogle Scholar
51Thornberry, NA, Lazebnik, Y. Caspases: enemies within. Science 1998;281:1312–16CrossRefGoogle Scholar
52Amarante-Mendes, GP, Green, DR. The regulation of apoptotic cell death. Braz J Med Biol Res 1999;32:1053–61CrossRefGoogle ScholarPubMed
53Paronlin, MB, Reason, IJ. Apoptosis as a mechanism of tissue injury in hepatobiliary diseases [in Brazilian Portuguese]. Arq Gastroenterol São Paulo 2001;38:3844Google Scholar
54Alam, SA, Ikeda, K, Oshima, T, Suzuki, M, Kawase, T, Kikuchi, T et al. Cisplatin-induced apoptotic cell death in Mongolian gerbil cochlea. Hear Res 2000;141:2838CrossRefGoogle ScholarPubMed
55Liu, W, Staecker, H, Stupak, H, Malgrange, B, Lefebvre, P, Van De Water, TR. Caspase inhibitors prevent cisplatin-induced apoptosis of auditory sensory cells. Neuroreport 1998;9:2609–14CrossRefGoogle ScholarPubMed
56Cheng, PW, Liu, SH, Hsu, CJ, Lin-Shiau, SY. Correlation of increased activities of Na + , K + -ATP-ase and Ca2 + -ATPase with the reversal of cisplatin ototoxicity induced by D-methionine in guinea pigs. Hear Res 2005;205:102–9CrossRefGoogle Scholar
57Cardinaal, RM, de Groot, JC, Huizing, EH, Veldman, JE, Smoorenburg, GF. Histological effects of co-administration of an ACTH(4-9) analog ORG 2766 on cisplatin ototoxicity in the albino guinea pig. Hear Res 2000;144:157–67CrossRefGoogle ScholarPubMed
58Kasse, CA, Hyppolito, MA, Cruz, OLM, Oliveira, JAA. Ototoxicity and otoprotection [in Brazilian Portuguese]. Rev Bras Med Otorrinolaringol 2008;4:105–15Google Scholar
59Rybak, L, Whitworth, C, Somani, S. Application of antioxidants and other agents to prevent cisplatin ototoxicity. Laryngoscope 1999;109:1740–4CrossRefGoogle ScholarPubMed
60Freitas, MR, Figueiredo, AA, Brito, GAC, Leitão, RFC, Carvalho, JV Jr, Gomes, RM Jr et al. The role of apoptosis in cisplatin-induced ototoxicity in rats [in Brazilian Portuguese]. Braz J Otorhinolaryngol 2009;75:745–52Google ScholarPubMed
61Sha, SH, Taylor, R, Forge, A, Schacht, J. Differential vulnerability of basal and apical hair cells is based on intrinsic susceptibility to free radicals. Hear Res 2001;155:18CrossRefGoogle ScholarPubMed
62Usami, S, Hjelle, OP, Ottersen, OP. Differential cellular distribution of glutathione – an endogenous antioxidant – in the guinea pig inner ear. Brain Res 1996;743:337–40CrossRefGoogle ScholarPubMed
63Muldoon, LL, Pagel, MA, Kroll, RA, Brummett, RE, Doolittle, ND, Zuhowski, EG et al. Delayed administration of sodium thiosulfate in animal models reduces platinum ototoxicity without reduction of antitumor activity. Clin Cancer Res 2000;6:309–15Google ScholarPubMed
64Hyppolito, MA, Oliveira, JAA, Lessa, RM, Rossato, M. Amifostine otoprotection to cisplatin ototoxicity: a guinea pig study using otoacoustic emission distortion products (DPOEA) and scanning electron microscopy [in Brazilian Portuguese]. Rev Bras Otorrinolaringol 2005;71:168273Google ScholarPubMed
65Hyppolito, MA, Oliveira, JAA, Rossato, M, Holanda, F. Cisplatin ototoxicity and otoprotector to ciliated cells by ginkgo biloba extract: anatomic and electrophysiologic study [in Brazilian Portuguese]. Rev Bras Otorrinolaringol 2003;69:504–11CrossRefGoogle Scholar
66Kalkanis, JG, Whitworth, C, Rybak, LP. Vitamin E reduces cisplatin ototoxicity. Laryngoscope 2004;114:538–42CrossRefGoogle ScholarPubMed
67Feghali, JG, Liu, W, Van De Water, TR. L-N-acetyl-cysteine protection against cisplatin-induced auditory neuronal and hair cell toxicity. Laryngoscope 2001;111:1147–55CrossRefGoogle ScholarPubMed
68Fetoni, AR, Ralli, M, Sergi, B, Parrilla, C, Troiani, D, Paludetti, G. Protective effects of N-acetylcysteine on noise-induced hearing loss in guinea pigs. Acta Otorhinolaryngol Ital 2009;29:70–5Google ScholarPubMed
69Riga, MG, Chelis, L, Kakolyris, S, Papadopoulos, S, Stathakidou, S, Chamalidou, E et al. Transtympanic injections of N-acetylcysteine for the prevention of cisplatin-induced ototoxicity: a feasible method with promising efficacy. Am J Clin Oncol 2013;36:16CrossRefGoogle ScholarPubMed